AdamsHPBendixenBHKappelleLJ, et al. (1993) Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke24(1): 35–41. DOI: 10.1161/01.STR.24.1.35.
2.
AmarencoPBogousslavskyJCallahanAIII, et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine355(6): 549–559. DOI: 10.1056/NEJMoa061894.
3.
AlakbarzadeVTaylorAScullyM, et al. (2018) Utility of current thrombophilia screening in young patients with stroke and TIA. Stroke & Vascular Neurology3(4): 231–236. DOI: 10.1136/svn-2018-000169.
4.
BhattDLEagleKAOhmanEM, et al. (2018) Smoking cessation and outcomes after ischemic stroke or TIA. Neurology91(4): e1–e12. DOI: 10.1212/WNL.0000000000005816.
GreenhalghT (2009) Patient and public involvement in chronic illness: Beyond the expert patient. BMJ338: b49. DOI: 10.1136/bmj.b49.
7.
HsuCYSaverJLOvbiageleB, et al. (2023) Association between magnitude of differential blood pressure reduction and secondary stroke prevention: a meta-analysis and meta-regression. JAMA Neurology80(5): 506–515. DOI: 10.1001/jamaneurol.2023.0218.
8.
LinHJWolfPAKelly-HayesM, et al. (1996) Stroke severity in atrial fibrillation. Stroke27(10): 1760–1764. DOI: 10.1161/01.str.27.10.1760.
9.
LipGYHNieuwlaatRPistersR, et al. (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest137(2): 263–272. DOI: 10.1378/chest.09-1584.
10.
LiuXJiangJLiD, et al. (2023) Antiplatelet treatment patterns and outcomes for secondary stroke prevention in the United Kingdom. Cardiology and Therapy12(4): 675–687. DOI: 10.1007/s40119-023-00332-7.
11.
MargolisKLO’ConnorPJMorganTM, et al. (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: The ACCORD randomized trial. Diabetes Care37(6): 1721–1728. DOI: 10.2337/dc13-2334.
12.
NICE (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181). Available at: www.nice.org.uk/guidance/cg181 (accessed 22 July 2025).
NICE (2022) Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128). Available at: www.nice.org.uk/guidance/ng128 (accessed 22 July 2025).
O’DonnellMJXavierDLiuL, et al. (2010) Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. The Lancet376(9735): 112–123. DOI: 10.1016/S0140-6736(10)60834-3.
19.
RahmanAAPlattRWBerardidS, et al. (2024) Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding, JAMA Network Open7(3): e243208. DOI: 10.1001/jamanetworkopen.2024.3208. Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2816687 (accessed 23 September 2025).
20.
RahmanHKhanSULoneAN, et al. (2023) Sodium-glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: a meta-analysis of randomized trials and systematic review. Journal of the American Heart Association12(16): e030578. DOI: 10.1161/JAHA.123.030578.
van der EndtVHWKloostermanMHeeringaJ (2022) Comprehensive comparison of stroke risk score performance in atrial fibrillation: a systematic review and meta-analysis. Europace24(11): 1739–1753. DOI: 10.1093/europace/euac096.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
